27480504|t|Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema
27480504|a|Chronic hand eczema (CHE) is a common inflammatory skin disease that affects approximately 10% of the population. Systemic alitretinoin has been shown to be effective in patients with CHE who are refractory to topical corticosteroids. To analyse the impact of alitretinoin on the skin barrier genes and protein expression in the skin lesions of patients with CHE. Fifteen patients with CHE were treated with 30 mg daily of alitretinoin for up to 27 weeks. Disease severity was assessed using a clinical score. Skin biopsies from all the patients were evaluated before and after therapy for the expression of Ki-67, various skin barrier genes and thymic stromal lymphopoietin (TSLP) by real-time quantitative polymerase chain reaction and immunohistochemistry. After alitretinoin application, an improvement in the clinical severity of CHE was observed in the majority of patients. Analysis of skin biopsies before treatment showed a significant increase in Ki-67 - positive cells in the suprabasal layer and a dysregulated expression of various skin barrier genes, such as claudin 1, loricrin, filaggrin and cytokeratin 10, which were normalized after treatment. TSLP was significantly upregulated in patients with CHE and also normalized after alitretinoin treatment and negatively correlated with filaggrin. Our data indicate that the expression of barrier genes and proteins was normalized following treatment with alitretinoin in patients with CHE. The change in expression levels of these genes correlated with the clinical efficacy, suggesting that alitretinoin exhibits a disease - modifying activity. TSLP is upregulated in CHE and seems to counteract filaggrin expression in the skin.
27480504	0	6	Impact	T080	C4049986
27480504	10	18	systemic	T169	C0205373
27480504	19	31	alitretinoin	T109,T121,T127	C0281666
27480504	32	41	treatment	T061	C0087111
27480504	45	57	skin barrier	T042	C2246986
27480504	58	62	gene	T045	C0017262
27480504	67	85	protein expression	T045	C1171362
27480504	89	97	patients	T101	C0030705
27480504	103	122	chronic hand eczema	T047	C1276092
27480504	123	142	Chronic hand eczema	T047	C1276092
27480504	144	147	CHE	T047	C1276092
27480504	161	186	inflammatory skin disease	T047	C3875321
27480504	200	213	approximately	T080	C0332232
27480504	225	235	population	T098	C1257890
27480504	237	245	Systemic	T169	C0205373
27480504	246	258	alitretinoin	T109,T121,T127	C0281666
27480504	280	289	effective	T080	C1704419
27480504	293	301	patients	T101	C0030705
27480504	307	310	CHE	T047	C1276092
27480504	319	329	refractory	T169	C0205269
27480504	333	356	topical corticosteroids	T121	C0304604
27480504	373	379	impact	T080	C4049986
27480504	383	395	alitretinoin	T109,T121,T127	C0281666
27480504	403	415	skin barrier	T042	C2246986
27480504	416	421	genes	T028	C0017337
27480504	426	444	protein expression	T045	C1171362
27480504	452	464	skin lesions	T047	C0037284
27480504	468	476	patients	T101	C0030705
27480504	482	485	CHE	T047	C1276092
27480504	495	503	patients	T101	C0030705
27480504	509	512	CHE	T047	C1276092
27480504	518	530	treated with	T061	C0332293
27480504	537	542	daily	T079	C0332173
27480504	546	558	alitretinoin	T109,T121,T127	C0281666
27480504	572	577	weeks	T079	C0439230
27480504	579	595	Disease severity	T080	C0521117
27480504	600	608	assessed	T052	C1516048
27480504	617	625	clinical	T080	C0205210
27480504	626	631	score	T081	C0449820
27480504	633	646	Skin biopsies	T060	C0150866
27480504	660	668	patients	T101	C0030705
27480504	674	683	evaluated	T058	C0220825
27480504	684	690	before	T079	C0332152
27480504	695	700	after	T079	C0687676
27480504	701	708	therapy	T061	C0087111
27480504	717	727	expression	T045	C1171362
27480504	731	736	Ki-67	T116,T129,T130	C0208804
27480504	746	758	skin barrier	T042	C2246986
27480504	759	764	genes	T028	C0017337
27480504	769	797	thymic stromal lymphopoietin	T116,T129	C0762640
27480504	799	803	TSLP	T116,T129	C0762640
27480504	808	856	real-time quantitative polymerase chain reaction	T063	C3179034
27480504	861	881	immunohistochemistry	T060	C0021044
27480504	889	901	alitretinoin	T109,T121,T127	C0281666
27480504	918	929	improvement	T077	C2986411
27480504	937	945	clinical	T080	C0205210
27480504	946	954	severity	T080	C0439793
27480504	958	961	CHE	T047	C1276092
27480504	982	990	majority	T054	C0680220
27480504	994	1002	patients	T101	C0030705
27480504	1004	1012	Analysis	T062	C0936012
27480504	1016	1029	skin biopsies	T060	C0150866
27480504	1030	1036	before	T079	C0332152
27480504	1037	1046	treatment	T061	C0087111
27480504	1056	1067	significant	T078	C0750502
27480504	1068	1076	increase	T169	C0442805
27480504	1080	1085	Ki-67	T028	C1334508
27480504	1088	1096	positive	T033	C1514241
27480504	1097	1102	cells	T025	C0007634
27480504	1110	1126	suprabasal layer	T026	C0243092
27480504	1133	1156	dysregulated expression	T045	C0017263
27480504	1168	1180	skin barrier	T042	C2246986
27480504	1181	1186	genes	T028	C0017337
27480504	1196	1205	claudin 1	T028	C1413460
27480504	1207	1215	loricrin	T028	C1416897
27480504	1217	1226	filaggrin	T028	C1414633
27480504	1231	1245	cytokeratin 10	T028	C1416714
27480504	1258	1268	normalized	T062	C1882115
27480504	1275	1284	treatment	T061	C0087111
27480504	1286	1290	TSLP	T116,T129	C0762640
27480504	1309	1320	upregulated	T044	C0041904
27480504	1324	1332	patients	T101	C0030705
27480504	1338	1341	CHE	T047	C1276092
27480504	1351	1361	normalized	T062	C1882115
27480504	1368	1380	alitretinoin	T109,T121,T127	C0281666
27480504	1381	1390	treatment	T061	C0087111
27480504	1395	1405	negatively	T033	C1513916
27480504	1406	1416	correlated	T080	C1707520
27480504	1422	1431	filaggrin	T116,T123	C0117738
27480504	1482	1487	genes	T028	C0017337
27480504	1492	1500	proteins	T116,T123	C0033684
27480504	1505	1515	normalized	T062	C1882115
27480504	1526	1535	treatment	T061	C0087111
27480504	1541	1553	alitretinoin	T109,T121,T127	C0281666
27480504	1557	1565	patients	T101	C0030705
27480504	1571	1574	CHE	T047	C1276092
27480504	1580	1586	change	T169	C0392747
27480504	1590	1600	expression	T045	C0017262
27480504	1601	1607	levels	T080	C0441889
27480504	1617	1622	genes	T028	C0017337
27480504	1623	1633	correlated	T080	C1707520
27480504	1643	1660	clinical efficacy	T080	C3850123
27480504	1678	1690	alitretinoin	T109,T121,T127	C0281666
27480504	1702	1709	disease	T047	C0012634
27480504	1712	1721	modifying	T169	C0392747
27480504	1722	1730	activity	T052	C0441655
27480504	1732	1736	TSLP	T116,T129	C0762640
27480504	1740	1751	upregulated	T044	C0041904
27480504	1755	1758	CHE	T047	C1276092
27480504	1783	1792	filaggrin	T116,T123	C0117738
27480504	1793	1803	expression	T045	C1171362
27480504	1811	1815	skin	T022	C1123023